Who makes Neuroncell-EX?

Neuroncell-EX is developed by Cytopeutics Sdn. Bhd..

Last reviewed 2026-04-19 · How we verify

Neuroncell-EX

Cytopeutics Sdn. Bhd. · Phase 2 active Biologic

At a glance

Generic name	Neuroncell-EX
Sponsor	Cytopeutics Sdn. Bhd.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

UCMSCs as Treatment for Patients With Acute Ischemic Stroke (Stroke Neuroncell-EX) (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Neuroncell-EX CI brief — competitive landscape report
Neuroncell-EX updates RSS · CI watch RSS
Cytopeutics Sdn. Bhd. portfolio CI